Novoprotein(SH:688137)2025-01-17 09:50Financial Performance - The company expects a net loss attributable to shareholders of the parent company for 2024 to be between -60 million and -45 million CNY, compared to a net profit of 12.84 million CNY in the same period last year [2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be between -77 million and -62 million CNY [2]. - The total profit for the previous year was 6.22 million CNY, with a net profit of 12.84 million CNY attributable to shareholders [3]. Business Strategy and Innovation - The company is enhancing its product line in target proteins, cytokines, recombinant antibodies, enzymes, and reagents, which has led to changes in sales structure and a decline in net profit [4]. - The company is focusing on innovation in the biopharmaceutical industry, increasing investment in mRNA vaccines, antibody drugs, gene and cell therapy, and other emerging fields, which has negatively impacted net profit due to high R&D expenses [5]. - The marketing team is being expanded to enhance market coverage and brand marketing, which has resulted in increased expenses affecting net profit [5]. Financial Reporting and Risks - The preliminary financial data has not been audited by registered accountants, and the company has not identified any major uncertainties affecting the accuracy of the forecast [6]. - Investors are advised to pay attention to investment risks as the forecast data is subject to change pending the audited annual report [7].